Holen Sie sich die Stockscreener-App
281.16
1.95%
-5.58
Handel nachbörslich:
281.16
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$286.74
Offen:
$289.33
24-Stunden-Volumen:
1.79M
Relative Volume:
1.07
Marktkapitalisierung:
$55.07B
Einnahmen:
$303.19B
Nettoeinkommen (Verlust:
$1.40B
KGV:
39.99
EPS:
7.03
Netto-Cashflow:
$-638.10M
1W Leistung:
-1.10%
1M Leistung:
+5.13%
6M Leistung:
+18.86%
1J Leistung:
+17.58%
1-Tages-Spanne:
$277.94
$289.33
1-Wochen-Bereich:
$277.94
$289.33
52-Wochen-Spanne:
$214.77
$296.65
Cencora Inc Stock (COR) Company Profile
Firmenname
Cencora Inc
Sektor
Branche
Telefon
610-727-7000
Adresse
1 WEST FIRST AVENUE, CONSHOHOCKEN
Vergleichen Sie COR mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
COR
Cencora Inc
|
281.16 | 55.07B | 303.19B | 1.40B | -638.10M | 7.03 |
|
MCK
Mckesson Corporation
|
682.49 | 85.55B | 344.58B | 2.83B | 1.63B | 21.84 |
|
CAH
Cardinal Health Inc
|
131.17 | 32.56B | 222.16B | 1.31B | -486.00M | 5.36 |
|
HSIC
Henry Schein Inc
|
63.08 | 8.04B | 12.50B | 314.00M | 421.00M | 2.44 |
|
OMI
Owens Minor Inc
|
6.51 | 534.60M | 10.42B | -38.77M | 323.54M | -0.51 |
Cencora Inc Stock (COR) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-12-04 | Fortgesetzt | Mizuho | Outperform |
| 2024-09-18 | Herabstufung | BofA Securities | Buy → Neutral |
| 2024-02-26 | Eingeleitet | Leerink Partners | Outperform |
| 2024-01-03 | Eingeleitet | Barclays | Overweight |
| 2023-12-14 | Eingeleitet | Wells Fargo | Equal Weight |
| 2023-03-31 | Eingeleitet | Citigroup | Buy |
| 2023-01-31 | Fortgesetzt | Evercore ISI | Outperform |
| 2022-10-11 | Hochstufung | BofA Securities | Neutral → Buy |
| 2022-08-22 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2022-07-11 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2022-06-07 | Hochstufung | Deutsche Bank | Hold → Buy |
| 2022-05-26 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2022-04-12 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2022-04-01 | Fortgesetzt | Credit Suisse | Outperform |
| 2021-03-12 | Fortgesetzt | Evercore ISI | In-line |
| 2021-02-04 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2021-02-02 | Hochstufung | Cowen | Market Perform → Outperform |
| 2021-01-06 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2021-01-06 | Hochstufung | Credit Suisse | Neutral → Outperform |
| 2020-12-10 | Herabstufung | Wells Fargo | Equal Weight → Underweight |
| 2020-12-03 | Eingeleitet | Mizuho | Neutral |
| 2020-08-06 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2020-07-15 | Eingeleitet | Barclays | Underweight |
| 2020-06-15 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2020-04-23 | Fortgesetzt | Credit Suisse | Outperform |
| 2020-04-16 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2020-04-13 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2020-04-01 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2020-03-17 | Hochstufung | Citigroup | Neutral → Buy |
| 2020-02-11 | Herabstufung | BofA/Merrill | Buy → Underperform |
| 2020-02-07 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2019-09-12 | Eingeleitet | Deutsche Bank | Hold |
| 2019-07-10 | Herabstufung | KeyBanc Capital Markets | Overweight → Sector Weight |
| 2019-04-11 | Eingeleitet | Guggenheim | Buy |
| 2019-04-10 | Herabstufung | BofA/Merrill | Buy → Underperform |
| 2019-04-10 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2019-02-11 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2019-01-17 | Eingeleitet | UBS | Buy |
| 2018-12-10 | Herabstufung | Jefferies | Buy → Hold |
| 2018-10-26 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2018-09-20 | Eingeleitet | Berenberg | Buy |
| 2018-07-17 | Fortgesetzt | Stifel | Hold |
| 2018-04-09 | Eingeleitet | MoffettNathanson | Buy |
| 2018-03-12 | Hochstufung | KeyBanc Capital Mkts | Sector Weight → Overweight |
| 2018-03-12 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2017-09-25 | Eingeleitet | JP Morgan | Neutral |
| 2017-09-22 | Eingeleitet | William Blair | Outperform |
Alle ansehen
Cencora Inc Aktie (COR) Neueste Nachrichten
Is Cencora, Inc. (COR) Outperforming Other Medical Stocks This Year? - Yahoo Finance
Lobbying Update: $60,000 of CENCORA INC. lobbying was just disclosed - Nasdaq
Will Cencora (COR) Beat Estimates Again in Its Next Earnings Report? - Yahoo Finance
Why Cencora (COR) is a Top Momentum Stock for the Long-Term - Yahoo Finance
Jim Cramer: Cencora (COR) Is a “Must-Own” Drug Middleman – Even If It Should Be Digitized Away - Insider Monkey
TD Cowen Adjusts Price Target on Cencora to $335 From $288, Keeps Buy Rating - marketscreener.com
Baird Adjusts Price Target on Cencora to $314 From $308, Keeps Outperform Rating - marketscreener.com
Jim Cramer is Bullish on These 10 Stocks - Insider Monkey
Morgan Stanley Adjusts Cencora Price Target to $288 From $263, Maintains Equal Weight Rating - MarketScreener
Morgan Stanley Increases Price Target for Cencora (COR) to $288 - GuruFocus
Jim Cramer Likes Cencora (COR) “Middlemen Always Work.” - Insider Monkey
Cencora to Announce Q2 Fiscal 2025 Results on May 7 - MSN
Jim Cramer Discussed These 12 Stocks - Insider Monkey
Here's Why You Should Add Cencora Stock to Your Portfolio Now - MSN
Cencora, Inc. (COR): A Bull Case Theory - MSN
Mizuho raises Cencora stock price target to $305, maintains outperform By Investing.com - Investing.com Canada
Evercore ISI Adjusts Price Target on Cencora to $320 From $280, Maintains Outperform Rating - marketscreener.com
Top 3 MedTech Stocks to Weather the Trump Tariff Turbulence - TradingView
Mizuho raises Cencora stock price target to $305, maintains outperform - Investing.com Australia
These 5 S&P 500 Winners Held Strong In Q1 — Can The Rally Continue? - Benzinga
Why We're Not Concerned About Cencora, Inc.'s (NYSE:COR) Share Price - simplywall.st
4 Low-Beta Healthcare Stocks to Beat Trump's Tariff Blues - TradingView
Has Cencora, Inc. (COR) Outpaced Other Medical Stocks This Year? - Yahoo Finance
Leerink Partners Adjusts Price Target on Cencora to $317 From $301, Maintains Outperform Rating - MarketScreener
Insiders At Cencora Sold US$16m In Stock, Alluding To Potential Weakness - Yahoo Finance
Cencora (COR) is a Top-Ranked Growth Stock: Should You Buy? - Yahoo Finance
Jim Cramer on Cencora (COR): “Smart Moves in the Drug Middleman Game!” - Insider Monkey
Jim Cramer Looked At These 23 Stocks Recently - Insider Monkey
Zacks Industry Outlook Highlights Cencora, Doximity and Pediatrix Medical - Yahoo Finance
Cencora Announces Date and Time for Second Quarter Fiscal 2025 Earnings Release - Business Wire
$290B Revenue Powerhouse Cencora Sets Critical Q2 Earnings Call Date - Stock Titan
Walden Group sale: DHL & Cencora show interest in deal - Trans.INFO
Cencora (COR) is a Top-Ranked Value Stock: Should You Buy? - Yahoo Finance
Cencora, Inc. (COR) Hit a 52 Week High, Can the Run Continue? - Yahoo Finance
AmerisourceBergen stock soars to all-time high of $271.17 By Investing.com - Investing.com South Africa
Cencora executive chairman sells $3.9 million in stock By Investing.com - Investing.com Canada
Cencora EVP Elizabeth Campbell sells $1.1 million in stock By Investing.com - Investing.com South Africa
Cencora EVP Elizabeth Campbell sells $1.1 million in stock - Investing.com
Cencora executive chairman sells $3.9 million in stock - Investing.com
Deutsche Bank Adjusts Cencora Price Target to $285 From $24 - MarketScreener
AmerisourceBergen stock soars to all-time high of $271.17 - Investing.com
Walgreens Boots Alliance, Inc. Reduces Stake in Cencora Inc. - GuruFocus
Logistics Firm Walden Is Said to Draw Interest from DHL, Cencora - MSN
Q4 Earnings Highlights: Cencora (NYSE:COR) Vs The Rest Of The Health Insurance Providers Stocks - The Globe and Mail
Insider Sell: Robert Mauch Sells Shares of Cencora Inc (COR) - GuruFocus
Cencora CEO Robert Mauch sells $1.3 million in stock - Investing.com India
Finanzdaten der Cencora Inc-Aktie (COR)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.63%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):